Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zalsenertant tetraxetan - Fusion Pharmaceuticals

Drug Profile

Zalsenertant tetraxetan - Fusion Pharmaceuticals

Alternative Names: 177Lu-DOTA-IPN01087; 3BP-227 Lutetium-177; 3BP227; 111In-IPN01087; 111Indium-labelled IPN01087; 177Lu-3BP-227; 177LU-DOTA-3BP-227; 177Lu-IPN01087; IPN 01087; IPN-01087 - Ipsen; IPN-01087A - Ipsen; Lutetium 177 - IPN 01087; Lutetium Lu 177 DOTA-3BP-227; Lutetium Lu 177 DOTA-IPN01087; Lutetium Lu 177 Zalsenertant tetraxetan; Lutetium-(177lu)-3BP-227; Lutetium-(177lu)-IPN01087; Zalsenertant Tetraxetan Lutetium LU-177

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer 3B Pharmaceuticals; Ipsen Biopharmaceuticals
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer in Germany (IV, Infusion)
  • 02 Jun 2021 Ipsen terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in Belgium, france, Netherlands, Switzerland, USA due to transfer of rights under purchase agreement (IV) (EudraCT2017-001263-20) (NCT03525392)
  • 01 Apr 2021 Fusion Pharmaceuticals acquires zalsenertant tetraxetan from Ipsen
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top